Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 3/20 | 0.38 |
| ▸ | CCNC | P24863 | 6/20 | 0.38 |
| ▸ | CDK8 | P49336 | 6/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20357375 | 1.00 | EPHX2 (0.41) | EPHX2MAPK14BRAFKDRTNNI3K | |
| SCHEMBL18615644 | 0.92 | EPHX2 (0.39) | EPHX2MAPK14BRAFRAF1GSK3A | |
| SCHEMBL20357325 | 0.92 | EPHX2 (0.39) | EPHX2MAPK14BRAFRAF1GSK3A | |
| SCHEMBL20357263 | 0.89 | EPHX2 (0.46) | EPHX2RAF1CCNCCDK8 | |
| SCHEMBL18615502 | 0.89 | EPHX2 (0.46) | EPHX2RAF1CCNCCDK8 | |
| SCHEMBL18615520 | 0.85 | EPHX2 (0.39) | EPHX2MAPK14KDRRAF1GSK3A | |
| SCHEMBL20357306 | 0.85 | EPHX2 (0.39) | EPHX2MAPK14KDRRAF1GSK3A | |
| SCHEMBL20357281 | 0.85 | MAPK14 (0.42) | EPHX2MAPK14BRAFKDRTNNI3K | |
| SCHEMBL18615639 | 0.85 | MAPK14 (0.42) | EPHX2MAPK14BRAFKDRTNNI3K | |
| SCHEMBL20357338 | 0.85 | BRAF (0.42) | EPHX2MAPK14BRAFRAF1CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345893-B1 | UREA DERIVATIVE AND USE THEREFOR | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3345893-B1 | UREA DERIVATIVE AND USE THEREFOR | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-10280145-B2 | Urea derivative and use therefor | TORAY INDUSTRIES, INC. (JP) | 2019-05-07 | — | — | US | disclosed |
| US-10280145-B2 | Urea derivative and use therefor | TORAY INDUSTRIES, INC. (JP) | 2019-05-07 | — | — | US | disclosed |
| US-20180237398-A1 | UREA DERIVATIVE AND USE THEREFOR | TORAY INDUSTRIES, INC. (JP) | 2018-08-23 | — | — | US | disclosed |
| EP-3345893-A1 | UREA DERIVATIVE AND USE THEREFOR | Toray Industries, Inc. (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-3345893-A1 | UREA DERIVATIVE AND USE THEREFOR | Toray Industries, Inc. (JP) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017038873-A1 | UREA DERIVATIVE AND USE THEREFOR | 東レ株式会社 | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280145-B2 | Urea derivative and use therefor | UTS2R, DDR1, WEE1 | EPHX2 4826/4885MAPK14 584/4885BRAF 100/4885 |
| US-20180237398-A1 | UREA DERIVATIVE AND USE THEREFOR | UTS2R, DDR1, WEE1 | EPHX2 4826/4885MAPK14 584/4885BRAF 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.